Dual Antibody Combination Therapy for IL-6 Dependent Tumours
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for multiple myeloma, a type of cancer characterized by abnormal Interleukin-6 (IL-6) production, are limited in effectively targeting IL-6 and its receptor, leading to incomplete inhibition of tumor cell proliferation and survival, as existing monoclonal antibodies do not fully abolish the effects of endogenous and exogenous IL-6 on myeloma cells.
Innovation Solution
A therapeutic drug combining an anti-human IL-6 monoclonal antibody (IL-6A) and an anti-human IL-6 receptor monoclonal antibody (IL-6RA) is used to specifically inhibit the biological activity of IL-6 and its receptor, thereby reducing IL-10 production and tumor cell proliferation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If a single monoclonal antibody (either anti-IL-6 or anti-IL-6R) is used, then the treatment targets one component of the IL-6 pathway, but the inhibition of tumor cell proliferation and survival is incomplete
Solution Approach 1:
The patent combines two monoclonal antibodies (anti-IL-6 and anti-IL-6R) into a single therapeutic regimen. This merging of two targeting mechanisms addresses the limitation of single-antibody therapy by simultaneously blocking both the cytokine and its receptor, thereby achieving more complete inhibition of tumor cell proliferation and survival pathways while managing the complexity through coordinated administration
2Reliability
If existing monoclonal antibodies are used alone, then the treatment is simpler to administer, but the effects of endogenous and exogenous IL-6 on myeloma cells are not fully abolished
Solution Approach 1:
The combination therapy merges two monoclonal antibodies with different targets (IL-6 and IL-6R) to achieve complete inhibition of IL-6 effects. This approach overcomes the insufficiency of single-antibody therapy by blocking both the ligand and its receptor, ensuring that neither endogenous nor exogenous IL-6 can stimulate tumor cell growth, while the administration protocol manages the operational complexity
3Reliability
If combination therapy with anti-IL-6 and anti-IL-6R is used, then complete inhibition of IL-6 pathway is achieved, but the treatment complexity increases
Solution Approach 1:
The patent applies merging by combining two monoclonal antibodies that target different components of the same pathway (IL-6 and IL-6R). This dual-targeting strategy achieves complete blockade of IL-6 signaling by preventing both ligand availability and receptor activation, thereby resolving the contradiction between achieving complete inhibition and managing treatment complexity through coordinated therapeutic design
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The prevent invention provides the use of a combination of an anti-human interleukin-6 monoclonal antibody (IL-6A) and an anti-human IL-6 receptor monoclonal antibody (IL-6RA) as effective components: (1) in the treatment of tumours produce Interleukin-10 which is induced by Interleukin-6, (2) in the treatment of multiple myeloma (plasmozytoma) produces Interleukin-10 which is induced by Interleukin-6 and (3) in the treatment of Interleukin-6 dependent tumours. Interleukin-10 leads to an enhanced proliferation of tumour cells.